Physician profile
Tanja Moennichmeyer
NPI 1770500779
$1,615.38
in general payments reported to CMS, 2019-2025
16 companies · $495 in 2025
The $495 reported for 2025 was more than what 83% of Occupational Vision providers received nationally (typical 2025 total: $169).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.28 · 2020: $79.30 · 2021: $278 · 2022: $166 · 2023: $338 · 2024: $245 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.21 | 2022-2025 | |
| Amgen INC. | $174.59 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $152.81 | 2024-2025 | Xdemvy |
| Allergan, INC. | $146.87 | 2020-2022 | |
| Horizon Therapeutics Plc | $124.00 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $123.36 | 2023-2025 | Miebo, Xiidra |
| Rxsight INC | $111.71 | 2021 | |
| Dompe US, INC. | $78.74 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.55 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $74.08 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $61.85 | 2024 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $51.50 | 2020-2025 | |
| Glaukos Corporation | $41.20 | 2024 | Ce-Marked Kxla System |
| Harrow Eye, LLC | $16.61 | 2024 | Vevye |
| Thea Pharma INC. | $14.02 | 2025 | Iyuzeh |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanja Moennichmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.